{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:24:15Z","timestamp":1759332255535},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2012,10,3]],"date-time":"2012-10-03T00:00:00Z","timestamp":1349222400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gen Thorac Cardiovasc Surg"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s11748-012-0160-x","type":"journal-article","created":{"date-parts":[[2012,10,2]],"date-time":"2012-10-02T02:01:42Z","timestamp":1349143302000},"page":"803-810","source":"Crossref","is-referenced-by-count":13,"title":["Immunohistochemical analysis of thymic carcinoma focusing on the possibility of molecular targeted and hormonal therapies"],"prefix":"10.1007","volume":"60","author":[{"given":"Mutsuko","family":"Omatsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Kunimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Mikogami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeharu","family":"Hamatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Shiokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Masunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Kitami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsutaka","family":"Kadokura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Morohoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,3]]},"reference":[{"key":"160_CR1","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1097\/JTO.0b013e3181f209a8","volume":"5","author":"P Str\u00f6bel","year":"2010","unstructured":"Str\u00f6bel P, Hohenberger P, Marx A. Thymoma and thymic carcinoma molecular pathology and target therapy. J Thorac Oncol. 2010;5:S286\u201390.","journal-title":"J Thorac Oncol"},{"key":"160_CR2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1200\/JCO.1996.14.3.737","volume":"14","author":"J Baselga","year":"1996","unstructured":"Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2\/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14:737\u201344.","journal-title":"J Clin Oncol"},{"key":"160_CR3","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","volume":"22","author":"LB Saltz","year":"2004","unstructured":"Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201\u20138.","journal-title":"J Clin Oncol"},{"key":"160_CR4","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/lary.20506","volume":"119","author":"SJ Wang","year":"2009","unstructured":"Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY. CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope. 2009;119:1518\u201330.","journal-title":"Laryngoscope"},{"key":"160_CR5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ijc.10980","volume":"104","author":"R Yoshimura","year":"2003","unstructured":"Yoshimura R, Matsuyama M, Segawa Y, Hase T, Mitsuhashi M, Tsuchida K, et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003;104:597\u2013602.","journal-title":"Int J Cancer"},{"key":"160_CR6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0030-4220(94)90119-8","volume":"78","author":"L Barnes","year":"1994","unstructured":"Barnes L, Rao U, Krause J, Contis L, Schwartz A, Scalamogna P. Salivary duct carcinoma. Part II: immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D and c-erbB-2 protein. Oral Surg Oral Med Oral Pathol. 1994;78:64\u201373.","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"160_CR7","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/JTO.0b013e3181e392a8","volume":"5","author":"N Girard","year":"2010","unstructured":"Girard N, Teruya-Feldstein J, Payabyab EC, Riely GJ, Rusch VW, Kris MG, et al. Insulin-like growth factor-1 receptor in thymic malignancies. J Thorac Oncol. 2010;5:1439\u201346.","journal-title":"J Thorac Oncol"},{"key":"160_CR8","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(07)60778-8","volume":"369","author":"J Cuzick","year":"2007","unstructured":"Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, LHRH-agonists in Early Breast Cancer Overview group, et al. Use of luteinizing-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomized adjuvant trails. Lancet. 2007;369:1711\u201323.","journal-title":"Lancet"},{"key":"160_CR9","first-page":"4819","volume":"30","author":"H Imai","year":"2010","unstructured":"Imai H, Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, et al. Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Res. 2010;30:4819\u201328.","journal-title":"Anticancer Res"},{"key":"160_CR10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00432-010-0882-z","volume":"137","author":"S Theocharis","year":"2011","unstructured":"Theocharis S, Klijanienko J, Giaginis C, Rodriguez J, Jouffroy T, Girod A, et al. Peroxisome proliferators-activated receptor-\u03b3 in mobile tongue squamous carcinoma: associations with clinicopathological parameters and patients survival. J Cancer Res Clin Oncol. 2011;137:251\u20139.","journal-title":"J Cancer Res Clin Oncol"},{"key":"160_CR11","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0046-8177(03)00291-0","volume":"34","author":"A Ouban","year":"2003","unstructured":"Ouban A, Muraca P, Yeatman T, Coppola D. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol. 2003;34:803\u20138.","journal-title":"Hum Pathol"},{"key":"160_CR12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","volume":"62","author":"K Yoh","year":"2008","unstructured":"Yoh K, Nishiwaki Y, Ishii G, Goto K, Kubota K, Ohmatsu H, et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer. 2008;62:316\u201320.","journal-title":"Lung Cancer"},{"key":"160_CR13","first-page":"127","volume":"37","author":"S Steinman","year":"2007","unstructured":"Steinman S, Wang J, Bourne P, Yang Q, Tang P. Expression of cytokeratin markers, ER-alpha, PR, HER-2\/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma(IDC) of the breast. Ann Clin Lab Sci. 2007;37:127\u201334.","journal-title":"Ann Clin Lab Sci"},{"key":"160_CR14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ygyno.2004.11.010","volume":"96","author":"P Lee","year":"2005","unstructured":"Lee P, Rosen DG, Zhu C, Silva EG, Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol. 2005;96:671\u20137.","journal-title":"Gynecol Oncol"},{"key":"160_CR15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000245894","volume":"76","author":"S Gunia","year":"2009","unstructured":"Gunia S, May M, Koch S, Dietel M, Erbersdobler A. Expression of CD44s in incidental prostate cancer is more strongly associated with Gleason scores on subsequent radical prostatectomies than conventional prognostic parameter. Pathobiology. 2009;76:286\u201392.","journal-title":"Pathobiology"},{"key":"160_CR16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jso.21277","volume":"99","author":"K Kaira","year":"2009","unstructured":"Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, et al. L-type amino acid transporter 1(LAT1) is frequently expressed in thymic carcinomas but is absent in thymoma. J Surg Oncol. 2009;99:433\u20138.","journal-title":"J Surg Oncol"},{"key":"160_CR17","first-page":"3344","volume":"58","author":"T Kubota","year":"1998","unstructured":"Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, et al. Ligand for Peroxisome proliferator-activated receptor \u03b3 (Troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998;58:3344\u201352.","journal-title":"Cancer Res"},{"key":"160_CR18","first-page":"1129","volume":"60","author":"TH Chang","year":"2000","unstructured":"Chang TH, Szabo E. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Cancer Res. 2000;60:1129\u201338.","journal-title":"Cancer Res"},{"key":"160_CR19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1006\/bbrc.2001.5640","volume":"287","author":"K Inoue","year":"2001","unstructured":"Inoue K, Kawahito Y, Tsubouchi Y, Khono M, Yoshimura R, Yoshizawa T, et al. Expression of peroxisome proliferator-activated receptor-in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun. 2001;287:727\u201332.","journal-title":"Biochem Biophys Res Commun"},{"key":"160_CR20","first-page":"1","volume":"0","author":"M Capelan","year":"2012","unstructured":"Capelan M, Pugliano L, De Azambuja E, Bozovic I, Saini KS, Sotiriou C, et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol. 2012;0:1\u201310.","journal-title":"Ann Oncol"},{"key":"160_CR21","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1158\/1078-0432.CCR-07-1118","volume":"13","author":"P Haluska","year":"2007","unstructured":"Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751, 871 in patients with refractory solid tumors. Clin Cancer Res. 2007;13:5834\u201340.","journal-title":"Clin Cancer Res"},{"key":"160_CR22","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1002\/cncr.25367","volume":"116","author":"PA Zucali","year":"2010","unstructured":"Zucali PA, Petrini I, Lorenzi E, Merino M, Cao L, Di Tommaso L, et al. IGF-1R and p-AKT expression in 132 resected thymoma and thymic carcinomas. Cancer. 2010;116:4686\u201395.","journal-title":"Cancer"},{"key":"160_CR23","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/JTO.0b013e3181d86a30","volume":"5","author":"SC Aisner","year":"2010","unstructured":"Aisner SC, Dahlberg S, Hameed MR, Ettinger DS, Schiller JH, Johnson DH, et al. Epidermal growth factor receptor, C-kit, and Her2\/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone. J Thorac Oncol. 2010;5:885\u201392.","journal-title":"J Thorac Oncol"},{"key":"160_CR24","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ygyno.2007.04.028","volume":"106","author":"S Bellone","year":"2007","unstructured":"Bellone S, Frera G, Landolfi G, Romani C, Bandiera E, Tognon G, et al. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for cetuximab-mediated therapy in recurrent\/metastatic disease. Gynecol Oncol. 2007;106:513\u201320.","journal-title":"Gynecol Oncol"},{"key":"160_CR25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00432-001-0319-9","volume":"128","author":"JD Henley","year":"2002","unstructured":"Henley JD, Koukoulis GK, Loehrer PJ Sr. Epidermal growth factor receptor expression in invasive thymoma. J Cancer Res Clin Oncol. 2002;128:167\u201370.","journal-title":"J Cancer Res Clin Oncol"},{"key":"160_CR26","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2741\/2098","volume":"12","author":"G Palmeri","year":"2007","unstructured":"Palmeri G, Marino M, Salvatore M, Budillon A, Meo G, Caraglia M, et al. Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci. 2007;12:757\u201361.","journal-title":"Front Biosci"},{"key":"160_CR27","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/bjc.1996.563","volume":"74","author":"DM Barnes","year":"1996","unstructured":"Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer. 1996;74:1445\u201351.","journal-title":"Br J Cancer"},{"key":"160_CR28","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","volume":"375","author":"HI Scher","year":"2010","unstructured":"Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Prostate Cancer Foundation\/Department of Defense Prostate Cancer Clinical Trials Consortium, et al. Antitumor activity of MDV3100 in castration-resistant prostate cancer: a phase 1\u20132 study. Lancet. 2010;375:1437\u201346.","journal-title":"Lancet"},{"key":"160_CR29","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/modpathol.2009.105","volume":"22","author":"M Kojika","year":"2009","unstructured":"Kojika M, Ishii G, Yoshida J, Nishimura M, Hishida T, Ota SJ, et al. Immunohistochemical differential diagnosis between thymic carcinoma and typeB3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms. Mod Pathol. 2009;22:1341\u201350.","journal-title":"Mod Pathol"},{"key":"160_CR30","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/cncr.21046","volume":"103","author":"S Sonobe","year":"2005","unstructured":"Sonobe S, Miyamoto H, Nobukawa B, Izumi H, Futagawa T, Ishikawa N, et al. Prognostic value of CD44 isoform expression in thymic epithelial neoplasms. Cancer. 2005;103:2015\u201322.","journal-title":"Cancer"}],"container-title":["General Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11748-012-0160-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11748-012-0160-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11748-012-0160-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T17:37:41Z","timestamp":1559410661000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11748-012-0160-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,3]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["160"],"URL":"https:\/\/doi.org\/10.1007\/s11748-012-0160-x","relation":{},"ISSN":["1863-6705","1863-6713"],"issn-type":[{"value":"1863-6705","type":"print"},{"value":"1863-6713","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,3]]}}}